Osocimab, formerly known as BAY 1213790, represents a groundbreaking monoclonal protein currently in clinical evaluation for the management of multiple hematologic cancers. This molecule specifically targets CD38, a https://hamzahzpbp104955.blog-gold.com/58136035/osocimab-a-deep-analysis-into-bay-1213790-and-its-promise